BioCentury | May 5, 2018
Product Development

Rebuilding Biogen’s brain

Biogen Inc. is still a long way from a full rebuild of its pipeline, with an Alzheimer’s disease-laden Phase III lineup that needs to diversify. But there’s progress in the early- to mid-stage programs where...
BC Week In Review | Feb 9, 2018
Clinical News

Biogen discontinuing natalizumab for stroke after Phase IIb miss

Biogen Inc. (NASDAQ:BIIB) discontinued development of natalizumab to treat acute ischemic stroke after the drug missed the primary and secondary endpoints in the Phase IIb ACTION 2 trial in the indication. Biogen markets natalizumab, a...
BC Extra | Feb 7, 2018
Clinical News

Biogen discontinuing natalizumab for stroke after Phase IIb miss

Biogen Inc. (NASDAQ:BIIB) discontinued development of natalizumab to treat acute ischemic stroke after the drug missed the primary and secondary endpoints in the Phase IIb ACTION 2 trial in the indication. Biogen markets natalizumab, a...
BC Extra | Jul 25, 2017
Company News

Spinraza sales drive Biogen's guidance bump

Biogen Inc. (NASDAQ:BIIB) reported 2Q17 earnings, raised its full-year revenue guidance for 2017 and laid out a five-part growth strategy that emphasizes multiple sclerosis, spinal muscular atrophy (SMA) and neuroscience. The company said faster-than-expected uptake...
BC Week In Review | May 19, 2017
Company News

Biogen adds to stroke portfolio with Cirara acquisition

Biogen Inc. (NASDAQ:BIIB) acquired acute ischemic stroke candidate Cirara glyburide (RP-1127) from Remedy Pharmaceuticals Inc. (New York, N.Y.). Remedy is to receive $120 million up front and is eligible for milestones and royalties. Biogen spokesperson...
BC Extra | May 15, 2017
Company News

Biogen adds to stroke portfolio with Cirara acquisition

Biogen Inc. (NASDAQ:BIIB) acquired acute ischemic stroke candidate Cirara glyburide (RP-1127) from Remedy Pharmaceuticals Inc. (New York, N.Y.). Remedy is to receive $120 million up front and is eligible for milestones and royalties. Biogen spokesperson...
BC Week In Review | Feb 29, 2016
Clinical News

Cirara glyburide: Additional Phase II data

Additional data from the double-blind, U.S. Phase II GAMES-RP trial in 77 patients with severe anterior circulation ischemic stroke who were likely to develop malignant edema showed that IV Cirara administered over a 72-hour period...
BC Week In Review | Oct 26, 2015
Clinical News

Glyburide: Preliminary Phase II data

Preliminary data from the double-blind, U.S. Phase II GAMES-RP trial in 77 patients with severe anterior circulation ischemic stroke who were likely to develop malignant edema showed that IV Cirara administered over a 72-hour period...
BC Week In Review | Sep 21, 2015
Clinical News

Glyburide: Phase IIa started

Remedy began an open-label, U.S. Phase IIa trial to evaluate IV Cirara in up to 10 patients who experienced an acute traumatic cervical SCI within 6 hours of dosing. Patients will receive a bolus of...
BC Week In Review | May 11, 2015
Clinical News

Cirara glyburide for injection: Completed Phase II enrollment

Remedy completed enrollment of 83 patients likely to develop malignant edema in the double-blind, placebo-controlled, U.S. Phase II GAMES-RP trial evaluating IV RP-1127. Remedy Pharmaceuticals Inc. , New York, N.Y.   Product: Cirara glyburide for injection...
Items per page:
1 - 10 of 13